Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | PF-06801591 |
Trade Name | |
Synonyms | PF06801591|PF 06801591|Sasanlimab |
Drug Descriptions |
PF-06801591 (sasanlimab) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32847983). |
DrugClasses | Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 86 |
CAS Registry Number | 2206792-50-7 |
NCIT ID | C124058 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Axitinib + PF-06801591 + SGN-TGT | Axitinib PF-06801591 SGN-TGT | 0 | 1 |
BCG solution + PF-06801591 | BCG solution PF-06801591 | 0 | 1 |
Binimetinib + Encorafenib + PF-06801591 | Binimetinib Encorafenib PF-06801591 | 0 | 1 |
PF-06801591 | PF-06801591 | 0 | 2 |
PF-06801591 + PF-06940434 | PF-06801591 PF-06940434 | 0 | 1 |
PF-06801591 + PF-07225570 | PF-06801591 PF-07225570 | 0 | 1 |
PF-06801591 + PF-07263689 | PF-06801591 PF-07263689 | 0 | 1 |
PF-06801591 + PF-07265028 | PF-06801591 PF-07265028 | 0 | 1 |